Yep...Everyone should go read about it's data compared to Tempol.....
and see what NIH thought of it last year even though they continue with it.
To say it is a competitor based on "Known" results from small studies,nothing has a safety profile compared to ADMP's Tempol with 2300 publications..How many does Merk's drug have??..*lol...
Thanks for the comparison found...Tic Toc Roll......
To be more clear, Merck's update on their own drug is stated in very favorable terms. But a quick search immediately digs up the Wikipedia page, and the topic of Safety Controversy is right near the top:
"In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties. A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it."
If anything, this shows the desperation big pharma feels to get a COVID response drug to market regardless of possible patient safety issues. Do any of their drug candidates have a 30 year long safety profile? Nope. Only one that I know of, and that would be Tempol, doesn't yet qualify as a Big Pharma candidate.
Do I think a little player like Adamis has the political power and influence to get it approved and to market? Not without a struggle. Can Big Pharma push it through to an EUA once reasonable efficacy is shown? They sure could!
So the obvious answer here is that one of these desperate Big Pharma players needs to step in, buy Adamis outright, and get this ball rolling toward a Tempol EUA so the world has a safe and effective (and cheap to manufacture, BTW...) solution to get us through this pandemic with minimal loss of human life. And if we as Adamis stockholders should happen to profit tremendously from this life-saving business move, then I'll just have to deal with it.
Message in reply to: Update on Merck's oral covid drug to show the competitive landscape that ADMP is facing. It's a 5 day oral treatment. Competition is heating up.
Market Data 
Markets 
AI
